Zentalis Pharmaceuticals, Inc. (ZNTL) Tops Q2 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ZNTL Hot Sheet
Join SI Premium – FREE
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) reported Q2 EPS of ($0.37), $0.17 better than the analyst estimate of ($0.54).
For earnings history and earnings-related data on Zentalis Pharmaceuticals, Inc. (ZNTL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Upgrades Aon Corp (AON) to Outperform, 'Best OG and Best Re-Rate Potential'
- Janus Living, Inc. (JAN) Reports Q3 Loss of $0.02 ; Offers Guidance
- BETA Technologies, Inc. (BETA) Misses Q3 EPS by 3c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
